UBS Maintains Buy on Veracyte, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 70.7%

Neg 0% Neu 0% Pos 70.7%

UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.

Comments

No comments yet. Be the first!